Back to search results

An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Relapsing Multiple Sclerosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Novartis Investigative Site, Darlinghurst, New South Wales, Australia

  • Novartis Investigative Site, Melbourne, Victoria, Australia

  • Novartis Investigative Site, Montpellier, France

  • Novartis Investigative Site, Nancy, France

  • Novartis Investigative Site, Rennes, France

  • Novartis Investigative Site, Bochum, Germany

  • Novartis Investigative Site, Essen, Germany

  • Novartis Investigative Site, Mainz, Germany

  • Novartis Investigative Site, Ulm, Germany

  • Novartis Investigative Site, Genova, GE, Italy

  • Novartis Investigative Site, Milan, MI, Italy

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Córdoba, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Valencia, Spain

  • Novartis Investigative Site, Bern, Switzerland

  • Novartis Investigative Site, Lausanne, Switzerland

  • Novartis Investigative Site, Zurich, Switzerland

Study leads

  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals

View source on ClinicalTrials.gov(opens in a new tab)